SCHEDULE 13G: Caligan Partners Discloses 9.99% Stake in Verrica Pharmaceuticals, Including Warrants
Beneficial Ownership Disclosure
Caligan Partners LP and David Johnson have disclosed a 9.99% beneficial ownership stake in Verrica Pharmaceuticals Inc., including shares issuable from warrants, as of December 31, 2024.
Summary
- Caligan Partners LP and David Johnson, its Managing Partner, have filed a Schedule 13G disclosing their beneficial ownership in Verrica Pharmaceuticals Inc.
- As of December 31, 2024, the Reporting Persons collectively beneficially own 9.99% of Verrica Pharmaceuticals' common stock.
- This ownership includes 8,426,966 shares of common stock issuable upon the exercise of warrants held by the Caligan Fund and Caligan Account.
- The reported beneficial ownership of 15,856,653 shares (shared voting and dispositive power) represents the total potential shares if all warrants were exercised without considering the 9.99% ownership blocker.
- Due to a 9.99% ownership blocker, the Reporting Persons cannot exercise warrants to the extent that their beneficial ownership would exceed 9.99% of the outstanding common stock.
- The 9.99% percentage is calculated based on 90,564,840 shares of common stock outstanding, which includes shares from the Company's underwritten public offering completed after November 21, 2024.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not convey positive or negative sentiment regarding the company's performance or outlook.
Positives
- The disclosure of a significant stake by an investment firm like Caligan Partners may signal confidence in Verrica Pharmaceuticals' future prospects.
Negatives
- NA
Risks
- The 9.99% ownership blocker limits the Reporting Persons' ability to fully exercise all their held warrants, potentially restricting their immediate voting power or influence beyond this threshold.
Future Outlook
This document is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Verrica Pharmaceuticals Inc. or the Reporting Persons regarding the company's future performance.
Industry Context
This filing indicates a significant investment by a specialized fund in a pharmaceutical company, which is a common occurrence in the biotech and pharma sectors where institutional investors often take substantial positions in companies with promising pipelines or market opportunities.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional investor's stake can influence market perception and potentially provide a degree of stability or interest in the stock.
Key Dates
| Date | Description |
|---|---|
| 2024-11-21 | Date of filing of the Company's Prospectus Supplement for its underwritten public offering, which established the outstanding share count used for beneficial ownership calculation. |
| 2024-12-31 | Date of event which requires the filing of this Schedule 13G statement, indicating the beneficial ownership position as of this date. |
| 2025-02-12 | Date the Schedule 13G statement was signed and filed by Caligan Partners LP and David Johnson. |
Keywords
Verrica Pharmaceuticals Inc., Caligan Partners LP, David Johnson, Beneficial Ownership, Schedule 13G, Common Stock, Warrants, Investment Adviser, Pharmaceuticals, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.